Literature DB >> 16673461

Future needs and directions for Shigella vaccines.

.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16673461

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN： 0049-8114


× No keyword cloud information.
  10 in total

1.  Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens.

Authors:  Andrea J Feller; Robin McKenzie; David N Taylor; Colleen C Woods; Shannon L Grahek; Dilara Islam; Malabi M Venkatesan; Thomas L Hale; August L Bourgeois
Journal:  Vaccine       Date:  2011-09-20       Impact factor: 3.641

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.

Authors:  J K Simon; M Maciel; E D Weld; R Wahid; M F Pasetti; W L Picking; K L Kotloff; M M Levine; M B Sztein
Journal:  Clin Immunol       Date:  2011-03-08       Impact factor: 3.969

4.  Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea.

Authors:  Anuradha Sinha; Ayan Dey; Giulietta Saletti; Pradip Samanta; Partha Sarathi Chakraborty; M K Bhattacharya; Santanu Ghosh; T Ramamurthy; Jae-Ouk Kim; Jae Seung Yang; Dong Wook Kim; Cecil Czerkinsky; Ranjan K Nandy
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

5.  Should the human microbiome be considered when developing vaccines?

Authors:  Rosana B R Ferreira; L Caetano M Antunes; B Brett Finlay
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

Review 6.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

7.  Characterization of Shigella sonnei in Malaysia, an increasingly prevalent etiologic agent of local shigellosis cases.

Authors:  Xiu Pei Koh; Chien Shun Chiou; Noni Ajam; Haruo Watanabe; Norazah Ahmad; Kwai Lin Thong
Journal:  BMC Infect Dis       Date:  2012-05-20       Impact factor: 3.090

8.  Molecular Characterization of Shigella sonnei: An Increasingly Prevalent Etiologic Agent of Shigellosis in Guizhou Province, Southwest of China.

Authors:  Shijun Li; Jianping Wang; Xiaoyu Wei; Ying Liu; Lu You; Xia Luo; Guangpeng Tang; Qiangzheng Sun; Changyun Ye; Jianguo Xu; Dingming Wang
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

Review 9.  Causes of impaired oral vaccine efficacy in developing countries.

Authors:  Edward Pk Parker; Sasirekha Ramani; Benjamin A Lopman; James A Church; Miren Iturriza-Gómara; Andrew J Prendergast; Nicholas C Grassly
Journal:  Future Microbiol       Date:  2017-12-08       Impact factor: 3.165

Review 10.  Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases.

Authors:  Asha Shelly; Priya Gupta; Rahul Ahuja; Sudeepa Srichandan; Jairam Meena; Tanmay Majumdar
Journal:  Viruses       Date:  2020-10-10       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.